Abstract Library

#4343 Ga68-DOTATATE imaging on a state-of-the-art total-body PET/CT scanner with reducing administered activity

Introduction: Long-field of view PET/CT scanners allows total body scanning resulting higher sensitivity than traditional PET/CT scanners offering possible lower dose and faster scans.

Conference:

Presenting Author: Santillan N

Authors: Navalkissoor S, Santillan N, Chowdhury A, Ferreira B, Toumpanakis C,

Keywords: SSR, Ga68 DOTATATE, Neuroendocrine tumour, Quadra,

#3281 Prediction of progression-free survival in patients with neuroendocrine tumors received 177Lu-Dotatate using circulating biomarkers

Introduction: Few circulating biomarkers are available for prediction of progression-free survival (PFS) in patients with advanced neuroendocrine tumors (NET) received 177Lu-Dotatate.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chen L, Gnanasegaran G, Mandair D, Toumpanakis C, Caplin M,

Keywords: PRRT, survival, ESR, creatinine, CgA,

#3208 Overall outcome of peptide receptor radionuclide therapy (PRRT) in treatment metastatic progressive neuroendocrine tumors (NETs): Survival, toxicity and prognostic factors

Introduction: NETs are a group of malignancies that frequently express somatostatin receptors which allow treatment with PRRT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, NET, peptide receptor radionuclide therapy PRRT,

#3206 Efficacy and safety of peptide receptor radionuclide therapy (PRRT) in patients with chronic kidney disease (CKD)

Introduction: The kidney is a dose-limiting organ in PRRT. Most clinical studies have focused on the safety of PRRT with normal or mildly impaired kidney function.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, peptide receptor radionuclide therapy PRRT, 177lu-DOTATATE, chronic kidney disease,

#3201 Safety and efficacy of peptide receptor radionuclide therapy in treating high-risk patients with extensive neuroendocrine tumors

Introduction: Neuroendocrine tumors (NETs) are a rare group of neoplasms. Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment modality for NETs that express somatostatin receptors (SSRs) on neuroendocrine cells’ surface. While many studies assessed the efficacy and safety in all NET patients, only a few focused on high-risk patients.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, NET, peptide receptor radionuclide therapy PRRT, 177lu-DOTATATE, extensive liver metastases, extensive skeletal metastases, extensive tumor burden,